Atria Investments Inc Raises Stock Holdings in Amgen Inc. $AMGN

Atria Investments Inc boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 26.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 52,324 shares of the medical research company’s stock after acquiring an additional 10,877 shares during the period. Atria Investments Inc’s holdings in Amgen were worth $17,126,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of AMGN. Capital World Investors increased its stake in Amgen by 11.5% during the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after purchasing an additional 1,935,876 shares during the period. Vanguard Group Inc. boosted its holdings in Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after purchasing an additional 961,975 shares in the last quarter. National Bank of Canada FI boosted its stake in Amgen by 237.7% in the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock valued at $346,076,000 after acquiring an additional 863,216 shares in the last quarter. Van ECK Associates Corp increased its position in shares of Amgen by 71.8% during the third quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company’s stock worth $383,254,000 after purchasing an additional 567,400 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in shares of Amgen by 91.6% in the third quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company’s stock valued at $221,607,000 after acquiring an additional 375,463 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Performance

Amgen stock opened at $336.45 on Thursday. The firm has a market capitalization of $181.58 billion, a PE ratio of 23.41, a price-to-earnings-growth ratio of 3.38 and a beta of 0.44. The stock’s 50 day moving average price is $351.05 and its 200 day moving average price is $342.80. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the firm posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts expect that Amgen Inc. will post 22.36 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.15%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. UBS Group increased their price objective on Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a report on Monday, April 13th. Barclays initiated coverage on Amgen in a report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 target price for the company. The Goldman Sachs Group raised their target price on Amgen from $415.00 to $425.00 and gave the company a “buy” rating in a report on Friday, May 1st. Erste Group Bank restated a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Finally, Royal Bank Of Canada raised their price target on Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $356.35.

Insider Activity

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.85% of the stock is currently owned by insiders.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.